Presentation

Company Profile
ArcticZymes Technologies is a Norwegian life sciences company focused on specialised, novel enzymes and immunomodulating beta-glucan technology. The company was previously called Biotec Pharmacon but was rebranded in 2020. In its core business segment of enzymes, the company develops, produces and markets recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics. ArcticZymes is based in Tromsø, Norway.

Recent highlights
In Q1 2021, ArcticZymes Technologies (AZT) had Q1 sales of NOK 40.4 million growing by 119% (Q1 2020: NOK 18.5 million). In June, the company announced the launch of their second-generation SAN HQ Enzymes. IN July, the company’s vaccine partner, ReiThera, announced the preliminary safety and immunogenicity data from the phase 2 part of the phase 2/3 COVITAR trial with its Covid-19 vaccine. The results show that the vaccine was well tolerated and induced a clear immune response in trial subjects.

Outlook
The phase III part of the COVITAR trial is expected to commence shortly, involving close to 10,000 volunteers, and it will assess efficacy in a non-inferiority design compared to a vector vaccine currently approved for COVID-19. At the same time, the company is progressing its pipeline and expects to launch several products in 2021, including M-SAN ELISA kit, Taq DNA Polymerase, Reverse Transcriptase, and other enzymes.